TACE vs SIRT vs RFA/MWA vs SBRT in Germany: Liver-Directed Treatment Comparison

Start with the clinical question, not the procedure name

Before comparing technologies, define what the liver team is trying to achieve. A local treatment may be used for disease control, treatment of a limited tumor burden, bridging or downstaging in a transplant pathway, treatment of liver-dominant metastatic disease, or management after another therapy. A technique that is reasonable for one goal may be inappropriate for another.

TACE: catheter-based chemotherapy plus embolization

Charité describes TACE as selective catheter treatment of highly vascularized liver tumors. Chemotherapy is delivered into tumor-feeding arteries and the blood supply is then embolized. TACE is especially established in HCC pathways, but specialist centers may also use it for selected other liver tumors. It can be repeated after reassessment rather than treated as a one-time procedure.

• Best understood as a transarterial treatment rather than direct tumor puncture
• Requires arterial access and selective catheterization
• Often involves post-embolization symptoms and short inpatient monitoring
• Repeat sessions may be planned depending on response and liver reserve

SIRT / Y-90: catheter-based internal radiation

SIRT, also called transarterial radioembolization, delivers Y-90-loaded microspheres through hepatic arteries. Charité and Freiburg describe its use for selected primary and secondary liver tumors. It requires a separate mapping and shunt-assessment pathway before therapeutic microspheres are administered, and treatment can be selective, lobar or staged.

• Uses internal radiation rather than locally delivered chemotherapy
• Requires angiographic mapping and nuclear-medicine planning
• Dosimetry and lung/extrahepatic shunt assessment are part of selection
• One or both liver lobes may be treated in separate stages

RFA / MWA: direct thermal destruction of a limited target

Radiofrequency and microwave ablation usually involve image-guided placement of an electrode or antenna directly into a tumor. Freiburg describes both techniques for selected tumors, with effectiveness influenced by lesion size, location and perfusion. The approach is most intuitive when a limited number of targets can be covered with an adequate ablation margin without unsafe injury to nearby structures.

• Direct percutaneous treatment rather than an arterial therapy
• Selection is strongly influenced by tumor size and geometry
• Large vessels can reduce heating through the heat-sink effect
• Bile ducts, bowel, gallbladder and diaphragm can limit safe access or margins

SBRT: non-invasive high-precision external-beam radiation

SBRT treats a defined liver target from outside the body using image-guided high-dose radiation in a limited number of fractions. German university centers including Charité, Heidelberg, Freiburg and UKE document extracranial stereotactic treatment for selected liver lesions. Unlike TACE or SIRT it does not depend on hepatic arterial catheterization, and unlike RFA/MWA it does not require inserting an applicator into the tumor.

• Can be considered when a target is well defined but surgery or percutaneous ablation is unsuitable
• Planning must protect healthy liver and nearby stomach, bowel, bile ducts and other organs at risk
• Respiratory motion may require breath-hold, gating, tracking or motion-specific margins
• The number of fractions depends on target geometry, prior radiation and normal-tissue dose limits

Tumor distribution often separates focal treatment from transarterial treatment

A small number of discrete lesions may be technically suitable for ablation or SBRT, while more multifocal liver-dominant disease can lead teams to consider a transarterial strategy. This is not a rigid rule: tumor biology, liver reserve, lesion location, vascular anatomy and previous therapy can outweigh lesion count alone.

Location can separate ablation from SBRT

A lesion may be difficult to puncture safely because of its position near bowel, diaphragm, major vessels or other structures, while radiation planning may offer a non-invasive alternative. The reverse can also occur: proximity to radiosensitive organs or prior radiation may constrain SBRT, while image-guided ablation may remain feasible. Technical suitability should be reviewed from the actual CT/MRI rather than inferred from tumor size alone.

Liver function can change the entire treatment strategy

Locoregional treatment still affects healthy liver. HCC guidance therefore considers liver function alongside tumor burden and performance status. A technically feasible intervention can still be inappropriate when liver reserve is poor or when another treatment offers a safer balance of benefit and risk.

Extrahepatic disease changes the meaning of a local liver treatment

For metastatic cancer, treating the liver does not automatically address disease elsewhere. The team should consider whether the cancer is liver-limited, liver-dominant or widely metastatic, and how local therapy fits with systemic treatment. The same principle applies to HCC when vascular invasion or extrahepatic spread changes the overall stage and treatment pathway.

Previous treatment matters when comparing the next option

Prior surgery, ablation, TACE, SIRT, external-beam radiation and systemic therapy can all alter anatomy, liver reserve and the feasibility of another local treatment. Comparison should therefore use the current imaging and full treatment history rather than a generic procedure table.

Questions to send to a German liver tumor board

A useful second-opinion request asks the team to explain the rationale for the recommended local strategy, not merely whether a procedure is available.

• What is the exact diagnosis and treatment goal?
• Why is this option preferred over surgery, transplantation, ablation, TACE, SIRT, SBRT or systemic therapy?
• How much healthy liver would be treated?
• What findings make the alternative options less suitable?
• Is one session expected or a staged/repeat pathway?
• How will respiratory motion or difficult tumor location affect treatment planning?
• How will response be measured and when?
• What would trigger a switch to another treatment strategy?

Do not compare these treatments only by headline price

The cost structure is different for each pathway. TACE can involve repeat catheter sessions; SIRT includes mapping, dosimetry and radioactive microspheres; ablation can vary with the number of lesions, applicators and anesthesia requirements; SBRT can vary with simulation, motion management, treatment planning and number of fractions. A meaningful financial comparison should use hospital estimates based on the same current imaging and clinical question.

Sources and review

This guide was last source-reviewed on 2026-09-08.

• EASL Clinical Practice Guidelines on Hepatocellular Carcinoma — European Association for the Study of the Liver ↗
• Trans-arterial chemo-embolisation (TACE) — Charité – Universitätsmedizin Berlin ↗
• Selective Internal Radiotherapy (SIRT) — Charité – Universitätsmedizin Berlin ↗
• Transarterial liver tumor treatment: TACE and SIRT — University Medical Center Freiburg ↗
• Tumor Ablation – radiofrequency and microwave ablation — University Medical Center Freiburg ↗
• Organ metastases – stereotactic radiotherapy / CyberKnife — Charité – Universitätsmedizin Berlin ↗
• Extracranial stereotaxy / SBRT — University Medical Center Hamburg-Eppendorf (UKE) ↗